Importantly, ENZ treatment enhanced the sensitivity of prostate cancer cells to RSL3, a selective ferroptosis inducer, indicating that AR inhibition potentiates ferroptosis (Fig. 7o, Supplementary Fig. 8l). Here, AR is linked to prostate cancer.